NR4A1 and cancer: Of the 18 articles that reported cancer hormone receptor status, five were based on all hormone-positive cancers, while the rest (n = 13) were based on ≥ 75% hormone receptor cancers (n = 5) or 60–75% hormone receptor cancers (n = 8).